Adagrasib and its Impurities
Adagrasib is an oral, small-molecule anticancer drug developed by Mirati Therapeutics. It is specifically designed to target and inhibit a mutated form of the KRAS protein known as KRAS G12C, which is commonly found in several types of cancers. Reference standards of Adagrasib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
